Table 2.
Association between prescription patterns and decrease in iPTH
| Prescription Pattern | iPTH | Unadjusted Model(4048 Sets) | Adjusted Modelc(4029 Sets) | |||||
|---|---|---|---|---|---|---|---|---|
| Cinacalcet | VDRA | Sets (n) | ACa (pg/ml) | Proportionb (%) | PD | 95% CI | PD | 95% CI |
| Not | Decreased | 561 | −67.8 | 45.8 | 0.00 | −0.05 to 0.05 | 0.01 | −0.03 to 0.06 |
| Not | Stable | 2153 | −56.7 | 45.3 | Reference | Reference | Reference | Reference |
| Not | Increased | 755 | −127.6 | 60.3 | 0.14 | 0.09–0.18 | 0.13 | 0.09–0.17 |
| Starting | Decreased | 131 | −141.8 | 61.8 | 0.15 | 0.07–0.24 | 0.19 | 0.10–0.28 |
| Starting | Stable | 307 | −205.1 | 67.4 | 0.22 | 0.16–0.27 | 0.25 | 0.19–0.31 |
| Starting | Increased | 141 | −266.8 | 80.9 | 0.34 | 0.27–0.40 | 0.34 | 0.25–0.42 |
iPTH, intact parathyroid hormone; VDRA, vitamin D receptor activator; AC, absolute change; PD, proportion difference; 95% CI, 95% confidence interval.
a
Means of AC in iPTH between reference and outcome visits.
b
Proportions of patients with decrease in iPTH.
c
Adjusted for age, sex, dialysis duration, iPTH levels, phosphorus levels, calcium levels, use of calcium- or non-calcium–based phosphate binders, single-pool Kt/V, and dialysate calcium.